Mesenchymal cells in the liver--one cell type or two?

The liver sinusoid contains specialized cells that regulate blood flow and tissue homeostasis. Hepatic stellate cells (HSC) are known for vitamin A storage and activation in response to liver injury. Prior research has shown that activated HSC contribute to fibrosis by increasing protein and DNA synthesis. However, liver myofibroblasts (MF) also respond to injury with similar activation patterns. No prior work had resolved whether HSC and MF are distinct or related cell types. This gap motivated investigations into their phenotypic and functional differences. Studies have proposed that MF in the portal and pericentral regions may act independently of HSC. The distinction between these cell populations remains unclear in the literature.

This study aimed to clarify whether hepatic stellate cells (HSC) and liver myofibroblasts (MF) are distinct cell types or functionally overlapping populations. The specific problem addressed is the lack of consensus on their identity and activation mechanisms. Researchers sought to compare gene expression and functional responses in HSC and MF. The motivation stems from the need to better understand liver fibrosis mechanisms. By analyzing activation markers and apoptotic behavior, the study aimed to resolve whether these cells are separate entities. The goal was to determine if HSC transform into MF or if they are distinct. This distinction could impact how liver fibrosis is modeled and treated. The findings may influence future studies on liver regeneration and disease progression.

The study compared quiescent and activated hepatic stellate cells (HSC) with liver myofibroblasts (MF) from portal and pericentral regions. Researchers analyzed gene expression patterns, focusing on fibulin-2 and IL-6 production. Activation markers such as DNA synthesis and protein production were measured in both cell types. Apoptotic behavior was assessed in vitro using CD95-ligand gene expression as a marker. The cells were cultured under similar conditions to observe activation responses. The study evaluated whether HSC could transdifferentiate into MF. Data were collected from multiple liver regions to ensure representativeness. The findings were compared to known characteristics of myofibroblasts in other organs.

Activated hepatic stellate cells (HSC) showed increased protein and DNA synthesis, adopting a myofibroblast-like phenotype. Liver myofibroblasts (MF) also increased protein and DNA synthesis in response to injury. MF expressed fibulin-2 and produced high levels of IL-6. Unlike activated HSC, MF did not undergo spontaneous apoptosis in vitro. HSC lacked CD95-ligand gene expression, while MF retained it. The study found no evidence of HSC transdifferentiating into MF. Instead, data supported the idea that HSC and MF are distinct populations. Both cell types contributed to fibrosis but through different mechanisms.

The authors concluded that hepatic stellate cells (HSC) and liver myofibroblasts (MF) are two distinct cell populations. They proposed that HSC and MF share some activation features but differ in gene expression and apoptosis. The study suggests that MF are comparable to myofibroblasts in other organs. No evidence was found to support transdifferentiation of HSC into MF. The findings imply that HSC and MF respond to liver injury through separate mechanisms. The authors emphasized the importance of distinguishing these cell types in fibrosis research. Their conclusion is based on gene expression and functional data. The implications suggest that liver fibrosis models should consider both cell populations separately.